ライフサイエンスコーパス: overcome resistance to

1 oguanosine monophosphate (6sGMP) prodrugs to overcome resistance to 6-thioguanine.

2 to show that one antibody-drug conjugate can overcome resistance to a previous one.

3 d at restoring lysosomal functionality might overcome resistance to ADC-based therapies and improve t

4 Preclinical data suggest that neratinib may overcome resistance to ado-trastuzumab emtansine (T-DM1)

5 This requires overcoming resistance to adoption, addressing infrastruc

6 Influential physicians willing to overcome resistance to advances were able to bring medic

7 To investigate therapeutic strategies to overcome resistance to anastrozole treatment, we have us

8 s ineffective against brain metastases, ISIM overcame resistance to anti-PD-L1 therapy, which rendere

9 ells, which could be a promising strategy to overcome resistance to anti-EGFR therapy.

10 d reprogrammed the tumor microenvironment to overcome resistance to anti-PD-1 in a subset of PD-1 adv

11 gest that FMT with beneficial microbiota can overcome resistance to anti-PD-1 inhibitors in advanced

12 ted whether dual Ang-2/VEGF inhibition could overcome resistance to anti-VEGF treatment.

13 t targeting GAD1 or GABA(B)R in mouse models overcomes resistance to anti-PD-1 immune checkpoint bloc

14 ors, B7x targeting inhibits tumor growth and overcomes resistance to anti-PD-L1 immunotherapy.

15 iangiogenesis drugs may be a new strategy to overcome resistance to antiangiogenesis therapy.

16 ultaneously may be an attractive strategy to overcome resistance to antiangiogenesis therapy.

17 xenografts suggests that inhibiting Dll4 may overcome resistance to antivascular endothelial growth f

18 poptosis; conversely, overexpression of XAF1 overcame resistance to apoptosis induction by IFN-beta.

19 antisense to DNA methyltransferase 1 (DNMT1) overcame resistance to apoptosis induction by IFNs with

20 geting growth factor receptors and pathways, overcoming resistance to apoptosis, and modifying epigen

21 with other agents have been investigated for overcoming resistance to AR-targeted therapies.

22 ositive (ER(+)) breast cancer cells, thereby overcoming resistance to aromatase inhibitors.

23 rt to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bc

24 en production by tumor cells by attIL12-TILs overcomes resistance to attIL12-T cell treatment and req

25 that BH3-mimetics targeting Bcl-xL may help overcome resistance to AURK inhibitors in cancer cells.

26 factors that synergize with venetoclax, and overcomes resistance to BCL2 inhibition.

27 s, we summarize small molecule strategies to overcome resistance to beta-lactam antibiotics.

28 , identify combination strategies capable of overcoming resistance to BiTE therapy, and have clinical

29 as a new strategy to enhance sensitivity or overcome resistance to bortezomib.

30 cessfully employed in clinical treatments to overcome resistance to both original and acquired T790M

31 eatment with the AR inhibitor, enzalutamide, overcame resistance to cabazitaxel.

32 r cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking(

33 t targeting TBK1 is an effective strategy to overcome resistance to cancer immunotherapy.

34 e CAFs within the TME is a novel strategy to overcome resistance to CART-cell therapy in MM.

35 ckade as a potential therapeutic strategy to overcome resistance to CDK4/6i in ER+/RB-deficient breas

36 s CDK2, CDK4, and CDK6 with a small-molecule overcomes resistance to CDK4/6 inhibition.

37 lity, thereby enhancing CDK4/6i efficacy and overcoming resistance to CDK4/6i in vitro.

38 hway is a potential avenue for preventing or overcoming resistance to CDK7 inhibitors.

39 lopment of novel biomarkers and therapies to overcome resistance to checkpoint blockade.

40 Moreover, 6-thio-dG overcomes resistance to checkpoint blockade in advanced

41 ndly sensitizes tumours to immunotherapy and overcomes resistance to checkpoint blockade.

42 ein disulfide isomerase (PDI) as a target to overcome resistance to chemoradiation, we developed a GB

43 ctylation, decreased DNA repair efficacy and overcame resistance to chemotherapy.

44 Overcoming resistance to chemotherapy is an area that ne

45 tosis and informs a therapeutic strategy for overcoming resistance to chemotherapy or immunotherapy i

46 4, whose overexpressions are correlated with overcoming resistance to cisplatin therapy, were also id

47 an adequate therapeutic strategy capable of overcoming resistance to clinically approved targeted th

48 triple combinatorial therapeutic strategy to overcome resistance to combined MEK inhibitor and PD-L1

49 To overcome resistance to conventional anti-androgens of hu

50 riggers caspase-dependent apoptosis, and can overcome resistance to conventional therapeutics (i.e.,

51 hinery, which offers promising prospects for overcoming resistance to conventional radiotherapy/chemo

52 changes in Tregs, but was not sufficient to overcome resistance to costimulatory molecule blockade i

53 es to manipulate the AML TME with the aim to overcome resistance to CPIs and other T-cell immunothera

54 Because of its potency, hCPT might overcome resistance to CPT in some cancer cells.

55 ce they synergize Cry toxins and are able to overcome resistance to Cry toxins.

56 n unexplored therapeutic target, which could overcome resistance to current antibody approaches.

57 ese data show the potential of BMS-986365 to overcome resistance to current ARPIs, regardless of AR L

58 could boost anti-tumour immune responses and overcome resistance to current immunotherapies.

59 on of multispecific checkpoint inhibitors to overcome resistance to current monospecific checkpoint a

60 targeted to achieve high selectivity and to overcome resistance to current therapeutics.

61 g new targets for combination therapies that overcome resistance to current treatments and promote lo

62 Therefore, there is an unmet need to overcome resistance to current venetoclax-based strategi

63 in the development of strategies designed to overcome resistance to currently available TKIs.

64 In models of multiple myeloma, CpdA overcame resistance to dexamethasone, doxorubicin, and m

65 tiveness of existing cancer therapies and to overcome resistance to drugs such as BRAF inhibitors (BR

66 Therefore, a combination strategy to overcome resistance to EGFR mono-targeted therapy is cli

67 l antibody cetuximab was previously shown to overcome resistance to EGFR TKIs.

68 on, abrogate HGF-mediated wound healing, and overcome resistance to EGFR- and MET-targeted therapy in

69 epresents a novel pharmacologic strategy for overcoming resistance to EGFR inhibitors in patients wit

70 llosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.

71 l 3-kinase (PI3K) is a promising approach to overcome resistance to endocrine therapy in breast cance

72 linically tractable combination strategy for overcoming resistance to endocrine therapy and CDK4/6 in

73 SLC7A5 as a potential therapeutic target for overcoming resistance to endocrine treatments in breast

74 Furthermore, LX1 was found to overcome resistance to Enza treatment, and its combinati

75 ylase inhibitors (HDACis) have been shown to overcome resistance to epidermal growth factor receptor

76 cent approval of third-generation therapies, overcoming resistance to epidermal growth factor recepto

77 This finding has clear implications for overcoming resistance to erlotinib.

78 ipulate Hippo signaling to boost response or overcome resistance to existing immune therapies.

79 pment of a new class of mTOR inhibitors that overcomes resistance to existing first- and second-gener

80 ial rationale for co-targeting cyclin/CDK to overcome resistance to EZH2 inhibition.

81 Overcoming resistance to Fas in asmase(-/-) hepatocytes

82 gents, and (3) development of molecules that overcome resistance to FLT3 inhibitors that arise as a r

83 akthrough, leading to complete remission and overcoming resistance to FLT3 inhibitors.

84 ressed NFkappaB activation in PDAC cells and overcame resistance to galunisertib and gemcitabine.

85 ntify novel strategies to prevent, delay, or overcome resistance to gemcitabine, one of the most wide

86 HER2+ breast cancers in order to prevent or overcome resistance to HER2 inhibitors.

87 essment of PI3K inhibition as an approach to overcome resistance to hormonal therapy, inhibitors with

88 geting of both AhR and IRAK1 in mouse models overcame resistance to ICB treatment.

89 ule PI3Kgamma inhibitor, such as IPI-549, to overcome resistance to ICB in patients with high levels

90 omplement adaptive immune responses and help overcome resistance to ICB.

91 c T cells, enhances anti-tumor immunity, and overcomes resistance to ICB therapy.

92 ADA can therefore be a therapeutic option to overcome resistance to ICIs in cancer patients.

93 ntific concepts that will potentially aid in overcoming resistance to ICT, which will require future

94 certain high-risk co-occurring mutations may overcome resistance to IDHi in AML.

95 iple effective agents are being developed to overcome resistance to imatinib.

96 resistance and explore ongoing approaches to overcome resistance to immune checkpoint blockade and ex

97 uch as faecal microbiota transplantation can overcome resistance to immune checkpoint blockade in pat

98 omes and identifies an RNA-based strategy to overcome resistance to immune checkpoint blockade.

99 roblast (CAF) and immune microenvironment to overcome resistance to immune checkpoint inhibition in P

100 ion (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in p

101 Finally, Ab-sumIL2 overcomes resistance to immune checkpoint blockade throu

102 Neutralizing GDF-15 holds promise in overcoming resistance to immune checkpoint inhibition in

103 t step in both macrophage classification and overcoming resistance to immunotherapies in cancer.

104 nts, suggesting that effective strategies to overcome resistance to immunotherapy are urgently needed

105 roach based on epigenetic therapy priming to overcome resistance to immunotherapy in pancreatic cance

106 increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy.

107 ss I, is currently in clinical evaluation to overcome resistance to immunotherapy.

108 for cotargeting stress-adaptive responses to overcome resistance to inhibitors of oncogenic pathway s

109 MET-targeted agents in coculture systems and overcame resistance to JNJ-38877605, crizotinib, and DN3

110 of tumor cell lines to provide a strategy to overcome resistance to kinase inhibitor therapy.

111 the TEAD transcription factor, GNE-7883, to overcome resistance to KRAS inhibitors.

112 Suppression of IRE1alpha overcame resistance to KRASi.

113 was active in Rh41-MAB391R cells and able to overcome resistance to MAB391, but MAB391 was not active

114 PARP inhibitors can overcome resistance to MAPK inhibitors by activating aut

115 Here, we aimed to identify new targets to overcome resistance to MEK + FAK inhibition (FAKi + MEKi

116 K inhibition, and nominate ERK inhibition to overcome resistance to MEK inhibition in histiocytoses.

117 we validated a drug combination predicted to overcome resistance to MEK inhibitors by coblockade of G

118 Our findings suggest novel approaches to overcome resistance to MEK inhibitors by combining AZD62

119 ERK inhibitors may have clinical utility in overcoming resistance to MEK inhibitor regimes; however,

120 o further enhance the antitumor activity and overcome resistance to MTPA-induced apoptosis in cancer

121 oach in enhancing therapeutic strategies and overcoming resistance to multiple TKI treatments.

122 n-responsive hypothalamic neurons, partially overcomes resistance to obesity in PTP1B(-/-) mice.

123 Carfilzomib also overcame resistance to other conventional agents and act

124 with proteins involved in DNA damage repair, overcomes resistance to other therapies and enhances ant

125 hat combined inhibition of PAK4 and PTK6 may overcome resistance to PAK4.

126 nflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade.

127 e findings indicate a promising mechanism to overcome resistance to PD-1 blockade by promoting immuno

128 reverse the immune effector dysfunction and overcome resistance to PD-1 blockade, as demonstrated bo

129 Loss of ADAR1 overcomes resistance to PD-1 checkpoint blockade caused

130 ithin a single tumor is thus an approach for overcoming resistance to PD-1 blockade that is unique in

131 hese findings provide important insights for overcoming resistance to PD-1 blockade.

132 s tumor survival in CRPC to identify ways to overcome resistance to PI3K inhibition.

133 fication of clinically viable strategies for overcoming resistance to platinum chemotherapy in lung a

134 function, induces apoptosis in MM cells and overcomes resistance to proteasome inhibitor bortezomib.

135 rials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient

136 efore determined whether CT-32615 could also overcome resistance to PS-341.

137 Moreover, proteasome inhibitors overcome resistance to quizartinib induced by mutations

138 evealing a potential therapeutic strategy to overcome resistance to RAF inhibition in a subset of BRA

139 rate that concomitant inhibition of IAPs can overcome resistance to RTK inhibitors in human malignant

140 lternative or combined strategies that might overcome resistance to RTK inhibitors in patients with c

141 n donor leukocyte infusions is important for overcoming resistance to second-set rejection induced by

142 pathways has been proposed as a strategy to overcome resistance to single-pathway inhibition in canc

143 th vital mitochondrial functions may help to overcome resistance to standard cancer therapy.

144 Overcoming resistance to taking opioids; initiating, tit

145 Use of rational drug combinations can overcome resistance to targeted drugs, but resistance ma

146 nstream point of vulnerability to prevent or overcome resistance to targeted drugs.

147 rategy to expand the treatment landscape and overcome resistance to targeted inhibition.

148 e metabolism may enhance the efficacy of and overcome resistance to targeted molecular cancer therapi

149 MET) pathways represents a novel approach to overcome resistance to targeted therapies in patients wi

150 metabolism of select cancer subtypes and to overcome resistance to targeted therapies.

151 AR system could benefit both sexes and help overcome resistance to targeted therapies.

152 inhibit melanoma progression and potentially overcome resistance to targeted therapy.

153 intersection is of potential significance in overcoming resistance to taxane chemotherapy in lethal p

154 ification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in m

155 optotic machinery to improve sensitivity and overcome resistance to the therapies that target oncogen

156 ovide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve pat

157 t be developed to inhibit CRC metastasis and overcome resistance to therapy associated with hypoxia.

158 the serial model approach to investigate and overcome resistance to therapy in SCLC.

159 d reveal new targets for drug development to overcome resistance to therapy.

160 Overcoming resistance to therapy is a major challenge in

161 ase (PI3K)/Akt/mTOR in WM, and mechanisms of overcoming resistance to therapy.

162 ecretion, and may be a therapeutic option to overcome resistance to TKIs.

163 Targeting TIM-1 provides an approach to overcome resistance to tolerance in clinical transplanta

164 ed to the development of novel strategies to overcome resistance to tolerance.

165 selenium-based dietary compounds may help to overcome resistance to TRAIL-mediated apoptosis in prost

166 tochondria constitute an important target in overcoming resistance to TRAIL in many types of tumors.

167 he receptors for NRG1 and HGF, respectively, overcome resistance to trametinib provided by these grow

168 To overcome resistance to transformations, ambitious policy

169 tumor bulk, suggesting potential regimens to overcome resistance to treatments and eradicate HNSCC me